AKT1 and type 2 diabetes mellitus: Carvacrol has previously been shown to restore GLUT4 membrane translocation mediated by PI3K/Akt signaling, lower blood glucose levels, and inhibit cardiac remodeling in both type 1 diabetes mellitus (T2DM) and type 2 diabetes mellitus (T2DM) mice (80).